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Abstract
Background: Acid sphingomyelinase (ASM) catalyses the hydrolysis of sphingomyelin into ceramide, which
acts as a lipid messenger that regulates important cellular functions. Deregulated ASM activity has been
reported for different common diseases, but the mechanisms regulating ASM activity are still debated. ASM
contains an exceptional signal peptide which is polymorphic due to a variable number of a hexanucleotide
sequence that determines the length of the hydrophobic core. We investigated the impact of the signal peptide
polymorphism on the regulation of ASM activity and secretion in vivo and in vitro. Methods and Results:
Subjects homozygous for the rare 4-repeat allele displayed significantly lower secreted ASM activity than
subjects homozygous for the common 6-repeat allele. In vitro, overexpression of ASM variants encoded by 2,
8 or 9 repeats resulted in a significantly lowered ASM secretion rate. Treatment of ASM-overexpressing cells
with tumour necrosis factor α induced secretion of ASM, and the secretion rate was highest for the most
common ASM variant encoding 6 repeats compared to other naturally occurring variants. Conclusion: We
provide evidence that the polymorphic ASM signal peptide regulates ASM secretion. It might be an
evolutionary mechanism to increase ASM secretion potential, whereas an increase in lysosomal ASM activity
is limited due to deleterious cellular effects.
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Abstract 
Background: Acid sphingomyelinase (ASM) catalyses the hydrolysis of sphingomyelin 
into ceramide, which acts as a lipid messenger that regulates important cellular functions. 
Deregulated ASM activity has been reported for different common diseases, but the 
mechanisms regulating ASM activity are still debated. ASM contains an exceptional signal 
peptide which is polymorphic due to a variable number of a hexanucleotide sequence that 
determines the length of the hydrophobic core. We investigated the impact of the signal 
peptide polymorphism on the regulation of ASM activity and secretion in vivo and in vitro. 
Methods and Results: Subjects homozygous for the rare 4-repeat allele displayed significantly 
lower secreted ASM activity than subjects homozygous for the common 6-repeat allele. In 
vitro, overexpression of ASM variants encoded by 2, 8 or 9 repeats resulted in a significantly 
lowered ASM secretion rate. Treatment of ASM-overexpressing cells with tumour necrosis 
factor α induced secretion of ASM, and the secretion rate was highest for the most common 
ASM variant encoding 6 repeats compared to other naturally occurring variants. Conclusion: 
We provide evidence that the polymorphic ASM signal peptide regulates ASM secretion. It 
might be an evolutionary mechanism to increase ASM secretion potential, whereas an increase 
in lysosomal ASM activity is limited due to deleterious cellular effects.
C. Rhein and M. Reichel contributed equally to this work.
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Introduction
Acid Sphingomyelinase (ASM, EC 3.1.4.12) generates ceramide by hydrolysing 
sphingomyelin, and it is therefore a key regulator of cellular sphingolipid metabolism [1]. 
The generation of ceramide is an important cellular reaction to stressful events [2, 3]. 
Ceramide molecules aggregate spontaneously and fuse to large macrodomains [4-6]. These 
macrodomains play an important role in signal transduction processes and impact signal 
cascades [7, 8]. Ceramide and its metabolites act as lipid messengers. They promote a 
variety of cellular processes, ranging from apoptosis, senescence, differentiation, migration, 
angiogenesis, and autophagy to inflammation [9-11]. The balance between apoptosis and 
proliferation in the cell is maintained by the complex interplay between two bioactive 
sphingolipids. Increased ceramide levels promote apoptosis, whereas an increase in the 
phosphorylated metabolite of ceramide, sphingosine-1-phosphate, counteracts this effect 
by inducing proliferation [12]. This ‘ceramide / sphingosine-1-phosphate rheostat’ concept 
describes how the balance between cell death and cell growth is regulated [12, 13]. Among 
the enzymes regulating the dynamic balance between the bioactive lipids, ASM holds a 
prominent position in that it generates the first bioactive molecule in this rheostat. 
The sphingomyelin phosphodiesterase 1 (SMPD1) gene coding for ASM gives rise to 
two distinct enzymes. Upon processing a common precursor protein inside the Golgi, 
the secreted form (S-ASM) is finally released into the extracellular space, whereas the 
lysosomal form (L-ASM) is targeted to the endo-lysosomal compartment [14, 15]. As a 
result of the differential post-translational processing, L- and S-ASM are characterised by 
distinct biochemical properties. L-ASM encounters zinc during its processing steps inside 
the lysosome, whereas the activity of S-ASM requires additional zinc [16]. Both forms are 
glycosylated during Golgi trafficking, but only S-ASM is converted into a complex glycosylated 
protein [17, 18]. Furthermore, both forms differ regarding their first amino acid at the 
N-terminus [16, 19-22]. 
Cytokines and other stimulating agents have differential effects on L- and S-ASM. In vivo, 
the induction of a systemic inflammation in mice by the application of lipopolysaccharide, 
tumour necrosis factor α (TNFα), or interleukin (IL) 1β is accompanied by increased S-ASM 
levels [23]. Data about the effects on L-ASM in this context has not been reported. The co-
regulation of S- and L-ASM activity was addressed in several cell culture systems. Romiti et al. 
[24] observed an increased S-ASM release from thrombin-stimulated platelets accompanied 
by decreased cellular L-ASM activity. Similarly, Jenkins et al. [15] observed increased S-ASM 
activity in MCF7 cells treated with phorbol myristate acetate accompanied by decreased 
L-ASM activity. The treatment with IL1β or TNFα in the same study resulted in increased 
S-ASM activity without affecting L-ASM activity [15]. Following treatment with IL1β, 
interferon (IFN) β, or IFNγ, Marathe et al. [25] observed that S-ASM activity increased by 2 to 
3.5-fold in human umbilical vein endothelial cells (HUVECs), and L-ASM activity decreased 
slightly. Thus, stimulation might selectively increase short-term S-ASM activity and secretion 
at the expense of L-ASM activity.
There is also emerging evidence that L- and S-ASM might differ in their contribution 
to specific pathologic states. Dramatically decreased L-ASM activity causes Niemann-Pick 
disease (NPD) types A and B, due to a variety of inherited missense mutations in the SMPD1 
gene [26]. Low ceramide levels can be found in different types of cancer like colon cancer [27] 
and glioma [28]. Elevated L-ASM activity in human primary material has been described for 
Alzheimer’s dementia [29], major depression [30], alcohol dependence [31] and infections 
[32]. Using murine models it was shown that L-ASM activity is increased in status epilepticus 
[33] and cystic fibrosis [34]. S-ASM activity is increased in patients suffering from alcohol 
dependence [35], Morbus Wilson [36], chronic heart failure [37], sepsis [38] and chronic 
hepatitis C [39]. S-ASM was also increased in murine models of arteriosclerosis [40], 
pulmonary edema [41] and emphysema [42]. 
Despite the huge number of clinically important missense mutations in the SMPD1 
gene, only a few reports have addressed the prevalence of common variants of ASM and their 
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possible contributions to human disease. In a re-sequencing analysis of the coding region 
of SMPD1 [43] we estimated that there are three common non-synonymous polymorphic 
sites with a frequency of >5% in the German population. An additional single nucleotide 
polymorphism (SNP) encoding the variant p.A487V, which was originally assumed to be 
a clinically relevant missense mutation, occurred with a frequency of about 1% [43]. The 
only common non-synonymous SNP that affects the mature ASM enzyme is rs1050239 
(c.1522G>A; p.G508R) with a minor allele frequency between 16% and 27% in different 
studies [44-46]. The polymorphism results in the amino acid substitution Gly>Arg at position 
508 in the C-terminus of ASM and it is associated with altered cholesterol levels, familial 
history of coronary artery disease [44], self-reported allergy and decreased in vivo S-ASM 
activity [45]. The two other common polymorphisms, rs1050228 (c.107T>C; p.V36A) and a 
hexanucleotide repeat (c.108GCTGGC(3_8); p.37LA(3_8)) reside within the putative signal 
peptide of the ASM pro-form that is not part of the mature enzyme. The signal peptide was 
shown to be essential for the production of an intact enzymatically active mature ASM, and 
ASM constructs with N-terminal truncations of the signal sequence lacked catalytic activity 
[17]. Wan and Schuchman [47] were the first to analyse the polymorphic hexanucleotide 
repeat encoding a variable number of Leu-Ala (LA) repeats. They identified five alleles 
with different repeat numbers, but the frequencies were similar for healthy individuals 
and patients with NPD types A and B. Recently, Dastani et al. [44] observed that the repeat 
number was associated with the prevalence of hypertension and plasma triglyceride levels 
in people with low high-density lipoprotein cholesterol. 
In the present study, we combined clinical and biochemical analyses to investigate the 
hypothesis that the polymorphic site in the signal peptide of ASM can affect ASM activity. 
We found evidence from both approaches that predominantly S-ASM activity is regulated 
differentially by the polymorphic site. In vivo, S-ASM activity was decreased in subjects 
homozygous for 4 repeats compared to those with the most prevalent motif of 6 repeats. In 
vitro studies elucidated that extreme length of the signal peptide decreases the secretion of 
ASM without affecting cellular ASM activity. Interestingly, the signal peptide polymorphism 
affects the secretion of ASM induced by the inflammatory cytokine TNFα. The secretion rate 
was significantly lower for the 4LA-repeat ASM variant compared to the ASM wild-type with 
6LA-repeat. Thus, despite the signal peptide being cleaved very early in ASM maturation, it 
has significant influence on the post-cleavage functioning of ASM. The signal peptide might 
serve as an evolutionary evolved mechanism to boost ASM secretion potential, although the 
increase in L-ASM activity is limited due to deleterious cellular effects. 
Materials and Methods
Clinical study
Study sample. ASM genotypes and ASM activity were initially analysed in 156 healthy individuals 
enrolled in the GENES study [45, 48-50]. Further data were obtained from the ASPECT control group (n=133) 
[31]. All studies were carried out at the Department of Psychiatry and Psychotherapy at the University of 
Erlangen-Nuremberg. The study protocols were approved by the local Ethics Committee and conducted in 
accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. 
Genotyping of ASM. Genomic DNA was isolated from whole blood using the Gentra Puregene Blood Kit 
(Qiagen, Hilden, Germany). The genotyping of rs1050239 was described previously [45]. The repeat number 
variation was determined by capillary electrophoresis of fluorescent-labelled PCR products on an ABI Prism 
3100 Genetic Analyzer (Applied Biosystems, Carlsbad, CA). Previously described oligonucleotides [47] ASM_
repeat_fw (5’-GGACTCCTTTGGATGGGCCT-3’) and ASM_repeat_rev*FAM (5’-CTTTGCAGATTGGGCAGG-3’) 
were used with the following PCR conditions: 1.5 U Tfi polymerase (Invitrogen, Darmstadt, Germany), 300 
µM dNTPs, 1.5 mM MgCl2, 240 nM of each oligonucleotide, and 50 ng of genomic DNA in a total volume of 15 
µl, which were incubated initially for 2 min at 94°C, and subjected to 30 cycles of 30 s at 94°C, 1 min at 58°C, 
and 1 min at 72°C, and finished for 3 min at 72°C on a Labcycler (Sensoquest, Göttingen, Germany). SNP 
rs1050228 was determined by PCR and cycle sequencing using the primers 5’-AGGGCTGGCTAGGGTCCAG-3’ 
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and 5’-AGCCCCAGCACTCCTTTCG-3’. PCR was performed in a total volume of 30 µl using 50 ng of genomic 
DNA, 3 U Tfi polymerase, 6 µl of 5× Tfi PCR reaction buffer, 250 µM dNTPs, 1.5 mM MgCl2, 200 nM of 
each oligonucleotide, and 5% v/v dimethyl sulfoxide (DMSO). The cycling conditions (35 cycles) were as 
described above. Sequencing was performed in a 10 µl volume, using 1 µl of PCR product, 0.5 µl of BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), 2 µl 5× BigDye Terminator sequencing buffer, 
500 nM oligonucleotide and 5% v/v DMSO. The reaction was subjected to 25 cycles of 30 s at 94°C, 15 s at 
58°C, and 60 s at 72°C, and analysed on an Applied Biosystems 3730 DNA Analyzer.
Determination of L- and S-ASM activity in blood samples. The determination of S- and L-ASM activity 
was conducted as described previously [45].
Overexpression studies of ASM variants
Construction of expression plasmids. Cloning of the ASM wild-type-FLAG-N2 construct [51] into the 
pmCherry-N1 expression vector (Clontech, Mountain View, CA, USA) was carried out using the In-Fusion 
Advantage PCR Cloning Kit according to the manufacturer’s instructions (Clontech, Mountain View, CA, USA). 
The primers for this procedure were: 5’-TCAGATCTCGAGCTCAAGCTTGCCGCCATGCCCCGCTACGGAGC-3’ 
(forward) and 5’-CTCACCATGGTGGCGACCGGTACGCAAAACAGTGGCCTTGG-3’ (reverse). The cycle 
parameters were as follows: initial denaturation at 95°C for 2 min, 35 cycles of 98°C for 20 sec, 68°C for 15 
sec, and 68°C for 1 min, and a final extension at 68°C for 5 min. Constructs were sequenced completely to 
exclude any mutations.
The QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to mutate 
the ASM wild-type sequence by PCR. Mutagenesis was done according to the manufacturer’s instructions 
starting from the ASM wild-type-cherry construct with 6 hexanucleotide repeats using the forward primer 
5’-TGGTGCTGGCGCTGGCTCTGT-3’ to obtain the ASM-cherry construct with 5 repeats. Successively, all 
further ASM-cherry variants containing different numbers of the repeat were derived. The cycle parameters 
were as follows: initial denaturation at 95°C for 1 min, 18 cycles of 95°C for 50 sec, 60°C for 50 sec, and 68°C 
for 6 min, and a final extension at 68°C for 7 min. Constructs were sequenced completely to exclude any 
spontaneous further mutations. 
Cell Culture. H4 cells (Promochem, Wesel, Germany) were cultured in DMEM supplemented with 10% 
(v/v) FCS and 4 mM L-glutamine. Cells were maintained at 37°C in a humidified atmosphere with 8.5% CO2 
as recommended by the supplier and monitored for potential mycoplasma infection using the MycoAlert 
Mycoplasma Detection Kit (Lonza, Cologne, Germany). All reagents used for cell culture were purchased 
from Biochrom (Berlin, Germany). For transfection purposes, cells were grown to 60% confluence in 6-well 
plates with 2 ml of culture medium. Transfections were performed by the calcium phosphate precipitation 
procedure. 7.5 µg of plasmid DNA were mixed with 2x N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic 
acid (BES) buffer [50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 6.98; all chemicals were obtained from 
Sigma-Aldrich (Munich, Germany)]. This mixture also contained 10 µl of 2.5 M calcium chloride. This was 
then incubated for 20 min at room temperature, and added to cells. The culture medium was changed 17 h 
after transfection. The transfection efficiency was approximately 70-80%, as determined by the number of 
GFP-positive cells after a parallel control transfection with the expression vector pmaxFP-green-C (Lonza, 
Cologne, Germany). Cells were serum-starved overnight and stimulated with TNFα (50 ng/ml; Promokine, 
Heidelberg, Germany) for 24 h. Transfected cells were lysed in RIPA buffer [50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (Sigma-Aldrich, Munich, Germany), into which 
were dissolved complete protease inhibitor tablets from Roche (Mannheim, Germany)]. Cell debris was 
removed by centrifugation at 1,000 g for 5 min at 4°C. Conditioned medium was collected and centrifuged 
at 800 g for 5 min at 4°C.
Acetone protein precipitation. To precipitate protein from the conditioned medium, the acetone protein 
precipitation method was applied. 1.5 ml of acetone that was pre-cooled to −20°C was added to 500 µl of 
conditioned medium. Upon vortexing, an incubation step was performed for 120 minutes at −20°C. After 
centrifuging for 10 minutes at 13,000 g, the supernatant was discarded, and the pellet was air-dried. For 
Western blotting, the pellet was dissolved in 50 µl of RIPA buffer.
Peptide-N-glycosidase F digestion (PNGase F). To remove N-linked glycosylation, PNGase F (Sigma-
Aldrich, Munich, Germany) digestion was applied according to the manufacturer’s instructions. 10 µl of 250 
mM phosphate buffer at pH 7.5 along with 2.5 ml of 2% SDS with 1 M 2-mercaptoethanol were added to 30 
µl of RIPA buffered cell lysate. Upon heating at 100 °C for 5 minutes, the mixture was cooled down and 2.5 
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ml of 10% (v/v) Triton X-100 was added. Incubation 
with PNGase F solution (0.01 U) was applied for 3 
hours at 37 °C. The cleavage pattern was assessed by 
subsequent Western Blot analysis.
Western blot analysis. The protein concentra-
tion of the cell extracts was determined using the 
Coomassie (Bradford) Protein Assay Kit (Pierce, 
Rockford, USA). Western blot analysis was conduct-
ed as described previously [43, 51]. The blots were 
incubated for 4 h at 4°C with the primary goat anti-
SMPD1 antibody (1:200; R&D, Abingdon, UK) and 
then for 1 h with secondary rabbit anti-goat IgG anti-
body, coupled to horseradish peroxidase (1:10,000; 
Dianova, Hamburg, Germany). All antibodies were 
diluted in 3% milk powder solution (Roth, Karlsruhe, 
Germany) and 0.1% Tween 20 in PBS (Sigma- 
Aldrich, Munich, Germany). Detection was per-
formed using the chemiluminescence (ECL select) 
Western blotting detection system (Amersham, 
Table 1. Characteristics of study sample and al-
lele frequencies of SMPD1 polymorphic sites in the 
GENES collective. HWE, Hardy-Weinberg equilib-
rium; SNP, single nucleotide polymorphism
Munich, Germany) and visualised on a high-sensitivity camera device (FluorSMax, Bio-Rad, Munich, 
Germany).
In vitro determination of L- and S-ASM activity. Activity of overexpressed ASM was determined using 
the fluorescent substrate BODIPY-C12-sphingomyelin (Invitrogen, Darmstadt, Germany). For L-ASM, 2 µl 
of the cell lysate supernatant (typically corresponding to 0.5–2 µg of protein) were added to 116 pmol of 
fluorescent substrate in sodium acetate buffer [200 mM sodium acetate pH 5.0, 500 mM NaCl and 0.2% NP-
40] in a total volume of 100 µl. After incubation for 0.5 to 3 h at 37°C, the fluorescent product ceramide and 
uncleaved substrate were extracted by the addition of 250 µl chloroform/methanol (2:1, v/v). Following 
vortexing and centrifugation, the lipid phase was concentrated in a SpeedVac vacuum concentrator and 
spotted on silica gel 60 plates (Macherey-Nagel, Düren, Germany). Ceramide and sphingomyelin were 
separated by thin layer chromatography using chloroform/methanol (4:1, v/v) as a solvent and quantified 
on a Typhoon Trio scanner (GE Healthcare, 488 nm excitation and 520 nm emission wavelengths, 280 V, 100 
µm resolution) with QuantityOne software (Bio-Rad, Munich, Germany). S-ASM was measured by the same 
procedure with additional 500 µM ZnCl2 in the reaction buffer using a sample volume of 1.5 µl serum-free 
medium and incubation times of 1–4 h. Measurements were performed at least in triplicates. The enzymatic 
activity of L-ASM was calculated as the rate of hydrolysis of sphingomyelin to ceramide per hour and per µg 
of protein (pmol/µg/h). The enzymatic activity of S-ASM in the medium refers to the amount of protein of 
the respective cell lysate sample (pmol/µg/h).
Data analysis
Deviation from Hardy-Weinberg equilibrium was assessed using chi-square test, and haplotypes 
were reconstructed from genotype data using the program PHASE v.2.1.1 [52]. Statistical analyses were 
performed with the software package IBM SPSS Statistics version 19. Variables were tested for normal 
distribution using the Kolmogorov-Smirnov test. The genetic effect on S- or L-ASM activity was calculated 
using ANOVA and Bonferroni post-hoc analysis. For cell culture experiments, statistical significance was 
calculated using t-test. A two-sided p-value <0.05 was considered to indicate statistical significance. All 
results are given as mean value ± standard deviation (SD).
Results
Analysis of the three common coding polymorphisms in the SMPD1 gene
We identified three non-synonymous polymorphic sites with a frequency of >5% (Fig. 
1A, Table 1). One of the polymorphisms, the SNP rs1050239 (c.1522G>A referenced to 
NM_000543.4; p.G508R referenced to NP_000534.3), is located in the C-terminus of ASM and 
associated with decreased S-ASM plasma abundance in vivo [45]. We therefore investigated 
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whether the two other common 
polymorphisms affect ASM activity 
in vivo as well. Notably, rs1050239 
is the only common variant that 
results in an amino acid substitution 
within the mature ASM enzyme. 
The two other sequence variants, 
SNP rs1050228 (c.107T>C; p.V36A) 
and the repeat number variation 
of a hexanucleotide sequence, lead 
to the modification of the signal 
Table 2. Frequency of estimated SMPD1 haplotypes in the 
GENES study
peptide of the pro-pro-form of ASM [18] (Fig. 1B). In previous reports, the polymorphic 
site was defined as the degenerated sequence 5’-CTGG(TC)(GT)-3’ [44, 47]. However, by 
considering the hexanucleotide motif as 5’-GCTGGC-3’, the genomic situation is reflected 
more precisely (for instance, see the description of rs3838786 and rs71056748 in dbSNP), 
and it allows for the resolution of a compound polymorphic site into two independent 
variations that can be described systematically (Fig. 1C). In addition, their relevance can be 
addressed separately from each other. 
We analysed the genetic configuration of SMPD1 in detail in the GENES collective of 156 
healthy young individuals (Table 1). The polymorphic hexanucleotide sequence occurred 
in our sample with 4, 5, 6, and 8 repeats. Alleles displaying 6 repeats were found with the 
highest prevalence (50.0%; corresponding to the 7-repeat allele in earlier studies that used 
the degenerated hexanucleotide sequence for description). Alleles with 5 repeats occurred 
with 41.3% (termed the 6-repeat allele in earlier studies). Alleles with four and eight repeats 
occurred with a much lower frequency (6.4 and 2.2%, respectively). These 4 alleles are 
combined into nine different genotypes (Fig. 1D). The majority of genotypes (86.5%, n=135) 
consisted of 5 and 6 repeats in homozygous or heterozygous configuration (5/5: 17.9%; 
5/6: 41.7%; 6/6: 26.9%). 9.6% of the genotypes (n=15) were heterozygous combinations 
of one frequent allele (either 5 or 6) and one rare allele (either 4 or 8). Of the remaining 
genotypes, five subjects were homozygous for 4 repeats, and one carried the combination 
4/8. Thus, more than 50% of the subjects exhibited a heterozygous repeat configuration. 
Based on the genetic data for all three polymorphisms, nine haplotypes were reconstructed 
using the PHASE program [52]. The predominant haplotype consisted of the combination 
c.107C – 6 repeats – c.1522G (C-6-G), accounting for nearly 50% of the alleles (Table 2). 
Another 40% of alleles carried the haplotype T-5-A or T-5-G. Thus, the c.107T allele was found 
nearly exclusively in combination with 5 repeats and was associated with 4 or 6 repeats in 
only 2.3%. Consequently, these haplotypes were termed the ‘naturally predominant’ ASM 
variants. As reported before by Dastani et al. [44], SNP c.1522A was preferentially present in 
combination with 5 hexanucleotide repeats. Thus, the genotypic distribution in our sample 
was similar to that described before.
The signal peptide polymorphism impacts S-ASM activity in healthy volunteers
Next, we calculated the effect of all three polymorphisms on the ASM activity in blood 
plasma (S-ASM) and in lysates of peripheral blood mononuclear cells (PBMC) (L-ASM) in 
156 healthy subjects of the GENES study by one-way ANOVA. Because of the strong effect 
of rs1050239 [45] and its association with the other two polymorphisms, we observed 
a significant association with S-ASM activity for all three polymorphisms when tested 
individually (all p<0.001). However, the influence of the c.107T>C polymorphism was 
lost when all three polymorphisms were taken into account simultaneously. None of 
the polymorphisms were associated with L-ASM activity (data not shown). For a clearer 
analysis, we selected subjects with homozygous repeat configurations (4/4, n=5; 5/5, n=28; 
6/6, n=42). This analysis confirmed the significant association of S-ASM activity with the 
number of hexanucleotide repeat (F=13.9, df=2, p=7.8x10-6; Fig. 2A). Bonferroni post-hoc 
analysis revealed statistically significant differences between subjects with 4 and 6 repeats 
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(p=0.013) and between those with 5 and 6 repeats (p=1.7x10-5). The results revealed that 
S-ASM activity associated with the 6/6 genotype was increased by 52% in comparison to the 
5/5 genotype and by 66% compared to the 4/4 genotype. Importantly, 4 and 6 repeats were 
both preferentially found in the haplotype with c.107C and c.1522G, making it reasonable 
to speculate that the difference in S-ASM activity results indeed from the different length 
of the signal peptide. In order to confirm this hypothesis statistically with a greater 
number of samples, we combined data from two different studies (GENES and ASPECT, see 
Fig. 1. Common coding poly-
morphisms in the SMPD1 
gene. A. Schematic representa-
tion of common polymorphic 
sites within the ASM protein. 
The sequence variant p.G508R 
(rs1050239; c.1522G>A) is 
located in the C-terminus 
of the mature enzyme, 
while p.V36A (rs1050228; 
c.107T>C) and the repeat 
number variation p.37LA(3_8) 
reside within a predicted 
transmembrane region of the 
putative signal peptide. The 
putative signal peptide (aa 
1–48) is indicated by a dark 
grey filling. B. The predicted 
transmembrane domain of 
the ASM signal peptide. The 
length of the repeat variation 
p.37LA(3_8) determines the 
hydrophobic core of the pre-
dicted transmembrane helix. 
The amino acid H62 is the pu-
tative signal peptide cleavage 
site. C. Resolution of the com-
pound polymorphic site in the 
ASM signal peptide into two 
distinct polymorphisms. The 
single nucleotide polymor-
phism c.107T>C is followed 
by a variable repeat number 
of the hexanucleotide motif 
5’-GCTGGC-3’ (upper lane). The number of repeats translates into the respective number of Leu-Ala di-
peptides which comprise the core of a putative transmembrane domain. The SNP c.107T>C determines 
whether the hypophobic core is extended at the N-terminal end by another Leu-Ala instead of a Leu-Val 
dipeptide. At the C-terminal site the hydrophobic core is terminated by a non-polymorphic Leu-Ser dipep-
tide (middle lane). Using the degenerated sequence 5’-CTGG(TC)(GT)-3’ for the description of the genomic 
situation obscures the compound nature of the polymorphic site (lower lane). The nucleotide sequence of 
the reference NM_000543.4 (Pos. 100–150) and the amino acid sequence of the reference NP_000534.3 
(Pos. 34–50) are given. D. Genotype prevalence. The genotype frequencies of the repeat motif varied highly 
in our study sample (n=156). The combinations of 5/6 (42%), 6/6 (27%), and 5/5 (18%) repeats are the 
genotypes with the highest prevalence.
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material and methods) and performed three-way ANOVA considering the effect of all three 
polymorphisms in a single analysis. This analysis confirmed that the hexanucleotide repeat, 
but not c.107T>C, had a significant effect on S-ASM activity independent from the influence 
of rs1050239 / c.1522G>A (hexanucleotide repeat: F=14.8, df=3, p=4.01x10-4; rs1050228: 
F=0.430, df=2, p=0.651; rs1050239: F=15.1, df=2, p=9.23x10-5). A graphical representation 
of the independent repeat motif effect is given in Fig. 2B.
The signal peptide polymorphism impacts S-ASM but not L-ASM activity in vitro
To further investigate the significance of the effect of the polymorphic hexanucleotide 
repeat for ASM biology, we performed in vitro studies using a cultured cell line. Plasmids 
coding for ASM variants with 1 to 9LA repeats combined with the LV dipeptide (p.V36) in the 
signal peptide and glycine (p.G508) at position 508 in the C-terminus of ASM were generated 
by site-directed mutagenesis and transiently overexpressed in H4 cells. The conditioned 
medium was collected and analysed for enzymatic activity of S-ASM. Overexpression of 
the ASM variant containing 6LA repeats, which is defined as the ASM wild-type (GenBank 
Accession Number NM_000543.4), significantly increased ASM activity levels by 120-fold 
compared to endogenous levels with a control plasmid. Similar results were obtained for ASM 
variants with 3, 4, 5, or 7LA repeats. In contrast, ASM variants containing the extreme motifs 
of 1, 2, 8, or 9LA repeats resulted in significantly lower levels of S-ASM activity compared to 
the ASM wild-type with 6LA-repeat (Fig. 3A).
To determine ASM protein expression levels, total proteins were precipitated from 
conditioned medium and subjected to Western blot analyses. Analogous to S-ASM activities, 
the expression of the protein corresponding to the size of the active ASM isoform was very 
strong upon overexpression of ASM variants with 3, 4, 5, 6, and 7LA repeats, but hardly 
detectable for ASM variants with the extreme motifs of 1, 2, 8, or 9LA repeats (Fig. 3B).
The overexpression of ASM wild-type with 6LA-repeat in H4 cells significantly increased 
the L-ASM activity in cell lysates by about 9-fold compared to endogenous levels. Except for 
the ASM variant with the 1LA-motif, no significant differences in ASM activity were found 
Fig. 2. The signal peptide polymorphism impacts S-
ASM activity in healthy volunteers. A. The 4-repeat 
genotype is associated with lower S-ASM activity. 
One-way ANOVA revealed statistically significant 
differences in S-ASM activity between healthy vol-
unteers homozygous for 4 (n=5), 5 (n=28), and 6 
(n=42) repeats (F=13.9, df=2, p=7.8x10-6). Bon-
ferroni post-hoc analysis revealed significant dif-
ferences between 4 and 6 (p=0.013) and 5 and 6 
(p=1.7x10-5) repeats. The boxplots show the median 
with the 25/75 percentiles. B. Graphical representa-
tion of the independent effects of the repeat length 
and c.1522G>A on S-ASM activity. Genetic data and 
z-transformed values for S-ASM activity from dif-
ferent studies (GENES and ASPECT, n=289) were 
combined. ANOVA confirmed that the hexanucleo-
tide repeat had a significant effect on S-ASM activ-
ity independent from the influence of rs1050239 / 
c.1522G>A. Numbers of homozygous samples in this 
analysis: 4, n=6; 5, n=42; 6, n=74. Data for S-ASM 
activity represent z-transformed values; error bars 
denote SD.
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Fig. 3. The signal peptide impacts 
secretion of ASM. A. S-ASM activ-
ity. Overexpression of the ASM wild-
type with 6LA-repeat significantly 
increased S-ASM activity levels com-
pared to control conditions. Similar 
results were obtained for ASM vari-
ants with 3, 4, 5 or 7LA repeats. In 
contrast, ASM variants containing 1, 
2, 8 or 9LA repeats exerted signifi-
cantly lower levels of S-ASM activ-
ity. H4 cells were transfected with 
7.5 µg of the respective ASM-cherry 
construct. Upon overnight serum-
starvation, conditioned medium 
was analysed for S-ASM activity us-
ing the enzyme activity assay. The 
cloning vector served as a negative 
control. The displayed data repre-
sent mean values of triplicates, and 
error bars denote SD. Results were 
replicated three times. Statistical 
significance was calculated with 
respect to the reference variant 
ASM wild-type (6LA) using t-test 
(*p<0.05, **p<0.01, ***p<0.001). B. 
Western blot analysis of conditioned 
medium. Overexpression of the ASM 
wild-type increased the expression 
levels of active ASM (85 kDa) in con-
ditioned medium compared to con-
trol conditions. Similar results were 
obtained for ASM variants with 3, 4, 
5 or 7LA repeats. In contrast, the ac-
tive 85 kDa form was hardly detecta-
ble for ASM variants with the extreme motifs of 1, 2, 8 or 9LA repeats. Protein was precipitated from conditioned 
medium and analysed by Western blotting. ASM-cherry variants were detected using an anti-ASM antibody. 
The cloning vector served as a negative control. C. L-ASM activity. Overexpression of ASM wild-type (6LA) in 
H4 cells significantly increased the L-ASM activity in the cell lysates compared to control. Except for the ASM 
variant with the 1LA-motif, no significant difference in ASM activity was found for the other ASM variants. Cell 
lysates were analysed for L-ASM activity using the enzyme activity assay. Otherwise, methods and statistics 
were applied as described in 3A.  D. Western blot analysis of cell lysates. Western blot analyses showed that 
cherry-tagged ASM variants were translated into proteins of the predicted sizes. With the exception of the ASM 
variant with the 1LA-motif, all other variants were expressed to a similar extent as ASM wild-type (6LA). Cell 
lysates were subjected to Western blotting. ASM-cherry variants were detected using an anti-ASM antibody. The 
cloning vector served as a negative control. 
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between the ASM variants (Fig. 3C). Western blot analyses showed that the variant ASM-
cherry constructs were translated into proteins of the predicted sizes. Using the antibody 
against ASM allows for the detection of an ASM-cherry pre-pro-form (ASM including 
the varying signal peptide (75 kDa) and the cherry-tag (30 kDa) adding up to a total of 
approximately 100 kDa), an ASM-cherry pro-form (ASM including cherry-tag but cleaved 
signal peptide), a C-terminally processed ASM form (ASM without cherry-tag; 75 kDa), and 
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the active ASM form (proteolytically cleaved ASM; 65 kDa). With the exception of the ASM 
variant with the 1LA-motif, all other variants were expressed to an extent similar to that of 
the ASM wild-type with 6LA-repeat (Fig. 3D).
The 1LA-motif does not serve as a functional signal peptide
To analyse whether the 1LA-motif serves as a functional signal peptide and is able to 
target the protein into the endoplasmic reticulum (ER), the glycosidase-sensitivity of the 
ASM signal peptide variants was investigated. Since N-glycosylation takes place selectively 
inside the ER lumen, this analysis indicates if a protein translocates into the ER [53]. Upon 
overexpression, cleared lysates were subjected to peptide-N-glycosidase F (PNGase F) 
digestion and subsequent Western blot analysis. PNGase F digestion leads to deglycosylation 
by releasing asparagine-linked (N-linked) oligosaccharides from glycoproteins, which 
results in a decrease of the protein mass of 10 kDa. Without PNGase F digestion, the ASM 
wild-type expression pattern was identical to those in the Western blot analysis in Fig. 3D. 
Upon PNGase F treatment, ASM protein bands were detected that were reduced to 90+, 90, 
65 and 55 kDa. The detection of glycosylated protein forms indicates the translocation of 
ASM wild-type into the ER. Compared to ASM wild-type, PNGase F treatment of ASM variants 
with LA-repeat>1 resulted in the same immunoreactive pattern. In contrast, the digestion of 
the 1LA ASM variant with PNGase F did not show protein bands that represent a glycosylated 
protein (Fig. 4). Thus, the 1LA-motif is not sufficient to serve as a signal peptide. The minimal 
requirement for a signal peptide seems to start from a 2LA-repeat motif.
TNFα-induced secretion of ASM is influenced by its signal peptide
Due to the impact of the ASM signal peptide on secretion, we investigated the ASM 
secretion process more closely. ASM secretion is promoted by inflammatory cytokines, as 
shown in in vitro and in vivo models [15, 23, 25]. To investigate the impact of the ASM signal 
peptide polymorphism on TNFα-induced secretion, H4 cells were transiently transfected 
with the naturally predominant ASM variants. Following stimulation of ASM-transfected 
cells with TNFα for 24 h, S-ASM activity increased and L-ASM activity decreased for all 
tested ASM variants (Fig. 5A). However, transfection of the ASM wild-type with 6LA-repeat 
resulted in a stronger TNFα-induced increase in S-ASM activity and a weaker decrease in 
L-ASM activity compared to the other natural variants. Regarding the ratio of S-ASM to 
L-ASM activity, the ASM wild-type with 6LA-repeat reached higher levels upon stimulation 
compared to the natural ASM variants with 4LA and 5LA repeats. The increase in the ratio 
of the S- to L-ASM activity of the 4LA-variant was significantly lower than for the ASM wild-
type with 6LA-repeat upon stimulation with TNFα (p=0.047), whereas the 5LA-variant 
reached intermediate levels (Fig. 5B). Thus, although the signal peptide is cleaved early in 
ASM maturation, the length of its hydrophobic core has significant impact on the secretion of 
ASM upon stimulation with TNFα.
Fig. 4. The 1LA-motif is not sufficient to translocate ASM into the endoplasmic reticulum. Upon PNGase F 
digestion, all detected ASM bands (see Fig. 3D) were shifted to protein sizes minus 10 kDa with the excep-
tion of the 1LA variant, for which no shift was detected. H4 cells were transfected with indicated variants, 
digested with 0.01U PNGase F for 22 h (“+”), and compared to control conditions (“−“) by Western blotting 
using an anti-ASM antibody. The cloning vector served as a negative control.
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Discussion
In this study, we combined clinical and biochemical approaches to elucidate how genetic 
polymorphisms located within the signal peptide of ASM might influence the regulatory 
function regarding expression of the protein. The signal peptide of ASM is remarkable in 
several respects. Firstly, usual signal peptides consist of fewer than 25 amino acids (aa) 
with a short positively charged N-terminal region (called n-region), a 7- to 15-residue-long 
central hydrophobic core (h-region), and a polar C-terminal region (c-region) which defines 
the cleavage site [54]. In contrast, the signal peptide of ASM consists of >48 aa comprising an 
extended n-region (≥26 aa), a predicted transmembrane domain (TMD) acting as an h-region 
(18 to 22 aa, depending on the prediction method used), and an ill-defined c-region which 
allows variable post-cleavage N-terminal starting points of the maturated enzyme [16, 19, 
22]. Thus, the signal peptide of ASM resembles more of an N-terminal anchor segment (type 
II signal anchor) [55, 56] that potentially encodes additional functions beyond the simple 
import to the endoplasmic reticulum such as specification of the targeting pathway, the 
efficiency of translocation, the timing of cleavage or post-cleavage functions [57]. Secondly, 
the hydrophobic core of the predicted TMD is variable in length due to a genetically stable 
Fig. 5. TNFα-induced secretion is influ-
enced by the ASM signal peptide. A. Influ-
ence of TNFα on S- and L-ASM activities. 
Upon stimulation with TNFα, S-ASM ac-
tivity levels increased significantly for all 
natural ASM variants, while L-ASM activ-
ity levels decreased significantly only for 
the 4LA and 5LA-variant compared to re-
spective control conditions. H4 cells were 
transfected with 7.5 µg of the respective 
ASM-cherry construct. Upon overnight 
serum-starvation, cells were stimulat-
ed with TNFα (50 ng/ml) for 24 h. Cell 
lysates were analysed for L-ASM activity, 
and conditioned medium was analysed 
for S-ASM activity using the enzyme ac-
tivity assay. The displayed data represent 
mean values of triplicates, and error bars 
denote SD. Results were replicated three 
times. Statistical significance was calcu-
lated with regard to the respective control 
condition using t-test (*p<0.05). B. Ratio 
between S- and L-ASM activity. Upon stim-
ulation with TNFα, the increase in the S- 
to L-ASM activity ratio of the 4LA-variant 
was significantly lower than for the ASM 
wild-type (6LA). The ratio of S- and L-ASM 
activity is indicated as the percentage of 
the respective control condition. The dis-
played data represent mean values of n=4 
independent experiments measured in 
triplicates, and error bars denote SD. Sta-
tistical significance was calculated with 
regard to the ASM wild-type (6LA) using 
t-test (*p<0.05). 
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polymorphic repeat number variation of a hexanucleotide motif encoding the dipeptide Leu-
Ala. Interestingly, the length of a TMD has a strong impact on the localization of the respective 
protein [58, 59]. Thus, the unusual structure of the ASM signal peptide might constitute a 
regulatory mechanism that controls the localization and thus the secretion of the enzyme. 
A similar effect on secretion exerted by a polymorphic signal peptide was described for 
apolipoprotein B (ApoB). Interestingly, ApoB displays a signal peptide polymorphism similar 
to that of the ASM, since it also comprises a Leu-Ala motif with an additional insertion (Leu-
Leu) or deletion (Leu-Ala-Leu) [60] that influences protein secretion rates [61]. In clinical 
studies, it has also been shown to influence the serum triglyceride levels [62], cholesterol and 
LDL-levels [63], cholesterol transport [64], and the onset of atherosclerosis and ischaemic 
heart disease [65, 66]. Thirdly, while the presence of a variable region does not necessarily 
prove a functional relevance, the non-random distribution of repeat numbers in the ASM 
gene implies that the repertoire of existing alleles has been shaped by selection [67]. We 
therefore hypothesized that the polymorphic signal peptide might affect ASM biology.
Importantly, there is also genetic evidence pointing to a functional role of the ASM 
signal peptide. In a study of 118 subjects of French-Canadian descent, Dastani et al. [44] 
analysed the association of common ASM polymorphisms with severely reduced plasma 
high-density lipoprotein (HDL) cholesterol levels. Although the authors’ original hypothesis 
of an association with low HDL-cholesterol levels could not be confirmed, they observed 
significant differences between affected subjects with 5/5, 5/6, and 6/6 configurations 
for hypertension and triglyceride levels. Since Dastani et al. compared only the three most 
common genotypes (which comprised nearly 90% of cases, similar to our study), this leaves 
the possibility that subjects who carry at least one of the rarer alleles and comprise <10% of 
the normal population are affected even more strongly. 
Considering the great genotypic diversity among carriers of rare alleles and the strong 
linkage disequilibrium with other functional polymorphisms such a hypothesis would be hard 
to prove. In our clinical study, we investigated genetic data from 156 volunteers of the GENES 
study along with their data on S-ASM activity determined from plasma. In a previous study, 
we found that S-ASM activity is a more sensitive marker for a genetic influence compared 
to L-ASM activity [45], probably because of the higher turn-over rate of L-ASM [15]. Indeed, 
we showed that S-ASM activity, but not L-ASM activity, was associated with the number of 
the hexanucleotide motifs in the signal peptide. In order to reduce the genetic diversity of 
the sample and to designate the specificity of the effect for the polymorphic signal peptide, 
we selected subjects with a homozygous repeat configuration and conducted multi-way 
ANOVA. As a result, we found that 4 repeats were associated with a statistically significant 
lower S-ASM activity compared to 6 repeats. Five repeats were associated with intermediate 
S-ASM levels, but this comparison was confounded by the preferential combination of 5 
hexanucleotide repeats with the minor allele of rs1050239 (c.1522A). Interestingly, as 
revealed by two-way ANOVA, only the haplotype consisting of 6 repeats together with the 
major allele of rs1050239 (which comprises nearly 50% of the predominant haplotype) 
gave rise to above-average S-ASM activity, while all other genetic combinations resulted in 
below-average S-ASM activity (see Fig. 2B).
Our in vitro data using cloned ASM cDNA encoding different numbers of the 
hexanucleotide repeat confirmed the importance of this motif for proper ASM processing. 
We defined the minimal requirement for the translocation of the nascent ASM peptide with 
two hexanucleotide repeats. Transfection of a cloned variant encoding only one repeat only 
slightly increased L- and S-ASM activity. A detailed analysis revealed that this variant is not 
glycosylated, indicating that it was not properly imported into the endoplasmic reticulum. 
In contrast, cDNA variants encoding between 2 and 9 repeats resulted in L-ASM activity 
increased by nine-fold compared to controls. However, L-ASM activity associated with varying 
repeat lengths was not different, which is in agreement with our observation in the clinical 
sample that common variants do not affect L-ASM activity. Interestingly, S-ASM activity 
showed different effects compared to L-ASM activity in our assay. While the transfection 
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of the most common variants increased S-ASM activity by 120-fold compared to controls, 
transfection of variants with extremely low or high repeat numbers increased S-ASM to a 
significantly lower extent. Further analyses revealed that the proteolytic maturation of ASM 
was hampered in these variants. 
Thus, our analyses revealed that the polymorphic ASM signal peptide affects L- and S-ASM 
differentially. Therefore, we questioned whether the polymorphic signal peptide would also 
affect ASM activity differentially under stimulating conditions. Our cell culture data showed 
a significant increase in S-ASM activity accompanied by a decrease in L-ASM activity upon 
stimulation with TNFα. The observation of a significant increase of S-ASM activity at the 
expense of decreased L-ASM activity is in line with other studies which addressed the co-
regulation of L- and S- ASM in response to stimulating agents [15, 24, 25]. However, we 
could additionally show that the ASM signal peptide polymorphism influences the balance 
between S-ASM release and the concomitant decrease in L-ASM activity significantly. The 
increase in the S- to L-ASM activity ratio of the 4LA-variant was significantly lower than for 
the ASM wild-type with 6LA-repeat upon stimulation with TNFα. 
This genetic effect could have important implications for the immunologic reactions of 
individuals carrying 4 repeats. Possibly, the difference in S-ASM activity between individuals 
homozygous for 4 repeats and those for 6 repeats in our in vivo study might result from 
the current individual and prevalent immunologic reaction. From an evolutionary point 
of view, the high number of repeats in humans with the higher adaptive potential in ASM 
activity regulation could be advantageous and more recent since the ASM encoding gene 
of other primate species with known sequence (Ensembl database) contains consistently 
less repeats. Alignment to the ASM wild-type sequence with 6LA-repeat in humans reveals 
a 5LA-repeat for Orangutan (Pongo abelii) and Macaque (Macaca mulatta), a 4LA-repeat 
for Chimpanzee (Pan troglodytes) and only a 3LA-repeat for Gorilla (Gorilla gorilla gorilla), 
Gibbon (Nomascus leucogenys), Bushbaby (Otolemur garnettii), Marmoset (Callithrix jacchus) 
and Mouse Lemur (Microcebus murinus).
Overall, the length of the ASM signal peptide TMD could be essential for the exact sorting 
and trafficking of ASM into highly specialised vesicles. It was shown that ASM co-localises 
with dysferlin to specific cellular vesicles during plasma membrane repair [68] and with 
syntaxin 4 upon stress responses to translocate to the plasma membrane via the exocytic 
pathway [69]. Interestingly, the syntaxin isoforms display distinct TMD lengths of their 
signal peptide that determine their localisation either to the Golgi or the plasma membrane 
[59]. Thus, the ASM TMD length seems to be optimised for its specific tasks in the cell.
However, there were some limitations of our study that should be considered. Although 
our clinical studies GENES and ASPECT comprised 289 healthy individuals in total, only a 
few individuals were homozygous for the rare allele with 4 repeats, which were needed for 
more powerful analyses. In our in vitro study, biochemical analyses of ASM resulted in very 
similar processing patterns for variants with 3 to 7 repeats, in contrast to the differential 
effects already seen for 4 repeats in vivo.
Taken together, our data provide first evidence that the length of the ASM signal peptide 
is essential for tapping the full secretion potential of the protein. The consequences of 
impaired ASM secretion for clinical populations have yet to be defined.
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